Evaluation of Alpha-1-Glycoprotein acid and Mucoproteins in patients with Paracoccidioidomycosis treated with Sulfametoxazol-Trimetoprim
DOI:
https://doi.org/10.36489/saudecoletiva.2021v11i67p6691-6704Keywords:
Paracoccidioidomycosis, Mucoproteins, Medication AdherenceAbstract
Alpha-1-acid glycoprotein (AGP) and mucoprotein are proteins of the inflammatory phase that increase their plasma concentrations when they present a response to the inflammatory state, representing a defense mechanism of the organism. The aim of the study was to evaluate the profile of these proteins in patients with chronic PCM treated with sulfamethoxazole-trimethoprim (SMX-TMP) and to associate the results found with epidemiological data, risk factors, symptoms, disease progression, and treatment outcome. In the methods adopted, the medical records of 244 patients with chronic PCM from 1998 to 2014 were analyzed. Of these, 134 (54.92%) patients underwent biochemical tests for inflammatory proteins during the course of the disease. Adult patients aged 30 to 50 years predominated 73 (54.48%), smokers 123 (91.79%), alcoholics 60 (44.78%). As a result, there was a decrease in inflammatory proteins after treatment (p = 0.01803). In conclusion, AGP and mucoproteins are useful as markers of the effect of therapy and inflammatory involution.